Sucampo Pharmaceuticals, Inc. Release: Phase 3 Clinical Trial Data of Lubiprostone in Japanese Patients with Chronic Idiopathic Constipation Presented at DDW 2011

BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation (CIC) patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients. The purpose of the studies was to confirm the treatment effect and safety profile of lubiprostone capsules in Japanese CIC patients.